ANI Pharmaceuticals Announces the Launch of Kionex Suspension

BAUDETTE, Minn., May 20, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Kionex (Sodium Polystyrene Sulfonate Suspension USP) for Oral or Rectal use. Kionex Suspension is the only commercially available therapeutically equivalent to the reference listed drug (RLD) SPS Suspension for Oral or Rectal use.

"The launch of Kionex Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our customers and patients in need. This launch is especially meaningful given the complexity of the development and is a testament to the tireless efforts of our strong R&D team to meet the updated guidance from the U.S. Food and Drug Administration,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.

U.S. annual sales for Sodium Polystyrene Sulfonate Oral / Rectal Suspension total approximately $30.3 million, based on March 2024 moving annual total (MAT) IQVIA data.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, visit www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those relating to the commercialization and potential sales of the product and any additional product launches from the Company’s generic pipeline, other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “plans,” “potential,” “future,” “believes,” “intends,” “continue,” other words of similar meaning, derivations of such words and the use of future dates.